glp-1 injection site reactions Shedding Light on Injection-site and Dermatological Risks of GLP-1RAs Tirzepatide-Induced Injection Site Reaction |

Institute of Human Genetics, Jena University Hospital, Jena 07747, Germany

In view of recent evidence supporting a sex-driven disparity in the GLP-1 response to small intestinal glucose infusion [42], we cannot rule out the possibility of a sex-related difference in the effects reported

Key Sources (selection) Cummings JL et al

Standard Dosage Recommendations: Typical concentration: Available as a 10 mg/mL solution in 5 mL vials Daily dosage: 1-2 mg (0.03-0.06ml or 3-6 units) subcutaneously Alternative recommendation: 0.2 mL delivered subcutaneously once daily Injection concentration range: 0.1% to 1.0% Administration Schedule: Frequency: Daily injections, preferably at the same time each day Recommended schedule: Monday through Friday (with weekends off) Important note: Injectable GHK-Cu should be administered under professional supervision due to risks associated with self-injection Oral/Ingestible Options Oral administration of GHK-Cu requires special formulation to prevent breakdown in the digestive system